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Abstract
Background: Family members are increasingly involved in the care of cancer patients, however many are not
prepared for this challenging role. Intervention-based studies are valuable to inform the most appropriate and
effective support for caregivers. Barriers in the recruitment of patient/caregiver dyads exist but the reasons for non-
participation are less well understood. This analysis determined the factors associated with participation in a
randomized controlled trial involving patient/caregiver dyads, reasons for non-participation and factors associated
with these reasons.
Methods: Patients with any type of cancer (other than non-melanoma skin cancer), and their caregiver were
recruited at four Australian health services. Eligible patients were invited to participate together with their caregiver
(N = 737). Non-participation data were collected from non-participants. Bivariate and binary logistic regression
analyses were conducted to examine factors associated with participation.
Results: Of the 737 eligible dyads, 521 (71%) declined participation. Dyad characteristics associated with
participation were caregiver gender, patient treatment modality and hospital type. The odds for participating were
almost two times greater for female than male caregivers (p = 0.005); 13 times greater for patients receiving
chemoradiotherapy compared to radiotherapy alone (p < 0.001); and three times greater for dyads attending a
private versus public hospital (p < 0.001). Reasons for non-participation were lack of interest (33%), lack of time
(29%), not requiring support (23%), too burdensome (15%); factors significantly associated with these reasons were
treatment modality, patient age, cancer type, and hospital type. Patients diagnosed with prostate cancer and
receiving chemotherapy alone were less likely to decline due to a lack of interest. Patients more likely to decline
due to lack of time were those aged 40–59 years and receiving chemotherapy alone. Patients who were more likely
to decline because they felt participation was too burdensome were those attending a private hospital for
treatment.
Conclusions: To optimize recruitment, it is recommended that special attention is given to different cancer types
and treatment modalities, gender and age. Approaching dyads at varied time points when their need for support is
high is recommended. This analysis provides important information for researchers undertaking randomized
controlled trials involving people diagnosed with cancer and their caregivers.
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Background
Involvement of family members and friends in the
provision of care for people diagnosed with cancer in
the home setting has become common place world-
wide [1]. In many instances, informal caregivers take
on caregiving responsibilities with little or no experi-
ence or support [2], resulting in increased caregiver
burden and poorer patient outcome [3–5]. Supporting
family members in their role as caregivers is critical
and can be achieved through intervention-based stud-
ies, which can vary in design and approach. Random-
ized controlled trials represent a good experimental
design but testing the efficacy of such interventions
requires adequate numbers of trial participants [6],
and recruitment of cancer dyads into clinical research
is challenging with accrual rates ranging from 5 to
50% [6–11]. Recruitment for couple-based interven-
tions requiring both the patient and the caregiver to
be involved in the intervention at the same time, is
known to be particularly difficult [6, 12–14].
When embarking on recruiting cancer dyads, under-
standing the barriers and facilitators is important. Identi-
fying and accessing caregivers to participate in studies
can be difficult due to caregivers’ time constraints and/
or own health issues [9, 11]. Further, demographic char-
acteristics, such as being male [7, 10, 14], being older
[15], and some clinical factors (e.g. cancer diagnosis
other than breast and prostate cancer, advanced disease)
[14], have been found to be associated with lower patient
accrual rates.
Establishing a profile of non-participants helps iden-
tify those who are less likely to participate in research
and provides opportunities to proactively address
these matters when designing research studies. How-
ever, an analysis of participation results is not often
reported in the literature [15].
The aim of this analysis was to examine the character-
istics associated with accrual into a multi-centred, ran-
domized controlled trial involving caregivers of cancer
patients, receiving treatment with curative intent.
Methods
Study design
From August 2013 to December 2014, patient/care-
giver dyads were recruited at three Australian public
health services and one private health service.
Potentially-eligible patients were identified by trained
senior nurses using treatment lists, at each participat-
ing health service. Those newly diagnosed with a pri-
mary cancer (approximately 2-months post-diagnosis),
attending cycles 2–5 of adjuvant chemotherapy and/
or fraction 2–10 for radiotherapy and receiving treat-
ment with curative intent, were eligible to participate.
From our pilot work, we determined this was the
optimal timeframe in which to approach prospective
participants, however, it should be noted that many
patients received more than five cycles of chemother-
apy/10 fractions of radiation treatment following en-
rolment into the trial. Each patient and his/her
caregiver were then approached by a trained re-
searcher during their scheduled treatment visit and
further eligibility checks were conducted (English pro-
ficiency, no cognitive dysfunction, patient has a care-
giver, patient and nominated caregiver both > 18
years). Eligible dyads were given a brief introduction
and a study package containing consent forms, infor-
mation sheets and baseline surveys. If the dyad was
interested in the study, initial consent was sought for
a researcher to re-contact them within 48 h to give
them time to discuss their participation in private ra-
ther than during their treatment session. If the care-
giver was not present at the treatment-related
appointment, consent was sought from the patient to
provide contact details of the caregiver, so that the
researcher could conduct the 48 h follow up call. In-
terested dyads were then telephoned to answer any
questions and to confirm participation. Consenting
dyads were asked to complete the consent form and
baseline survey, and return them to the researchers
using the reply paid envelope provided. If the dyad
was unavailable at the time of calling, up to seven
call attempts were made to contact the dyad to seek
confirmation of participation. Non-participation oc-
curred if the dyad or either one of them declined par-
ticipation, or after seven unsuccessful attempts to
contact them. For non-consenting dyads, the reason
for refusal was documented (one main reason per
dyad only as it was not deemed appropriate to bur-
den them with too many questions given their desire
not to participate). Interested dyads were asked to
complete the consent form and baseline question-
naires (patient and caregiver survey) and post them
back to the researchers using a reply-paid envelope.
Figure 1 outlines the recruitment and consent process
of the PROTECT study. Consenting dyads were then
randomized into the telephone-based intervention
group or the telephone-based attention control group
[16]. Participants in both groups received three tele-
phone calls; one at the beginning of the program, as
well as one month and four months later. While the
intervention group received a tailored intervention pro-
gram delivered by both the Victorian and South Australian
based Cancer Council telephone information and support
services/helplines (known as ‘Cancer Council 13 11 20’,
which is the largest non-government provider of cancer
support services in Australia), caregivers in the attention
control group received a sham intervention with a re-
searcher providing them with the contact details of the
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Cancer Council telephone information and support
service, which they could contact if needed. If they
chose to call that service, they received the usual 13
11 20 telephone support not the tailored intervention.
In addition to the baseline survey, caregivers were
asked to complete questionnaires one month and six
months post-intervention, and patients completed
questionnaires one month post-intervention. Patient
data were collected to assess the potential impact of
the caregiver intervention on patient outcomes. A
more complete description of the study and findings
on the efficacy of the intervention on reducing care-
giver burden are described elsewhere [17].
Ethics approval was obtained from Deakin University
Human Research Ethics Committee: 2012–083, the re-
spective committees at each participating health service
and the two Cancer Councils. The study was registered
with the Australian New Zealand Clinical Trial Registry:
ACTRN12613000731796.
Data collection and analyses
Patient information was obtained through medical re-
cords and included: age, gender, postcode, cancer diag-
nosis, treatment type (chemotherapy alone, radiotherapy
alone, chemoradiotherapy), and hospital type (public,
private). Caregiver information was collected from con-
senting dyads through the baseline questionnaire and in-
cluded, age, gender, type of relationship to patient
(spouse/partner, parent, adult child, other relative,
friend/other), whether or not they resided with the pa-
tient (yes/no), household size and level of education
(secondary school, diploma/certificate, university de-
gree). Caregiver data from non-participating dyads was
restricted to caregiver gender. The socioeconomic status
(SES) of participants was measured by assigning the
Socio-Economic Indices for Areas (SEIFA) decile rank-
ings (1–10) to the postcode [18]; a method developed by
the Australian Bureau of Statistics which has been
widely used in research studies [19, 20]. To represent
relative advantage/disadvantage, rankings were grouped
into the following categories: low SES (1–3), middle SES
(4–7), and high SES (8–10). Reasons for decline were
grouped into the following categories: lack of time, lack
of interest, not requiring support, too burdensome
(questionnaires/study period too long, caregiver and/or
patient too unwell). We were unable to collect reasons
from those dyads who could not be contacted for the 48
h follow-up call (n = 24). All types of cancers other than
Fig. 1 Flowchart outlining the recruitment and consent process of the PROTECT study
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non-melanoma skin cancer were included and these
were grouped as follows: breast, bowel, prostate/testicu-
lar, haematological (e.g. leukemia, lymphomas), lung/
head and neck/ brain/ melanomas, and others (e.g.
gynecological, bladder, kidney, soft tissue).
The data were analysed using Statistical Package for
Social Sciences (SPSS), version 21. Descriptive statistics
were performed to describe sample characteristics. Bi-
variate analyses were performed to compare participants
and non-participants on demographic variables includ-
ing caregiver gender, patient age and gender,
socio-economic status (SES), cancer diagnosis, treatment
type and hospital type. Associations between these vari-
ables and the reasons for non-participation were also ex-
amined. Variables which produced significant results in
bivariate analyses were then included in the binary logis-
tic regression (multivariable analysis) to ascertain the ef-
fects of caregiver and patient factors on the likelihood
that dyads participated in the study. Results of the ana-
lyses were considered statistically significant when p <
0.05.
Results
A total of 839 patients were screened, 102 (12%) were
excluded as either the patient or the caregiver did not
meet eligibility criteria including 81 patients (10%)
who did not have a caregiver (Fig. 1). From a total of
737 eligible patient/caregiver dyads, 521 (71%) de-
clined participation. Reasons stated by dyads for
non-participation were ‘lack of interest’ (n = 163,
33%), ‘lack of time’ (n = 147, 29%), ‘not requiring sup-
port’ (n = 113, 23%), and ‘too burdensome’ (n = 74,
15%).
Profile of participants and non-participants
The profile of participants and non-participants are pre-
sented in Table 1.
Non-participant profile
Caregiver data available for those dyads who declined
participation were limited to gender and there were
slightly more male (54%) than female caregivers in
this group. Non-participating patients’ mean age was
59.96 (SD: 12.56), 64% of patients were female and
most of them came from middle (36%) and high
(35%) socio-economic areas. Forty-six percent were
diagnosed with breast cancer, 11% with prostate/tes-
ticular cancer, and 11% with a haematological cancer.
The majority (86%) attended a public hospital for
treatment and 60% were receiving radiotherapy alone.
Participant profile
Of the participating dyads, caregiver mean age was 56.75
(SD: 12.94), more than half (57%) were female caregivers
and 32% percent had a tertiary education. The majority
(79%) were in a spousal/partner relationship with the
person they provided care for, and 84% lived in the same
household. Patient mean age was 56.29 (SD: 12.25), 56%
of patients were female and most of them came from
middle (41%) and high (37%) socio-economic back-
grounds. Forty-one percent were diagnosed with breast
cancer, 14% with prostate/testicular cancer, and 12%
with a haematological cancer. Two-thirds (67%) attended
a public hospital for treatment and 33% were receiving
radiotherapy alone.
Factors associated with participation
Bivariate analysis revealed participation was associated
with caregivers being female (p = 0.012), patients receiv-
ing chemotherapy alone (p = 0.003), chemoradiotherapy
(p < 0.001), and being treated in a private hospital (p <
0.001) (Table 1). In the multivariable analysis, these vari-
ables remained significantly associated with participation
(Table 2). Dyads where the caregiver was female were al-
most twice as likely to participate compared to those
where the caregiver was male (OR = 1.69 [95% CI, 1.2 to
2.4], p = 0.005); patients receiving chemoradiotherapy in-
creased the odds of participating in the study by almost
13 times compared to receiving radiotherapy alone (OR
= 12.91 [95% CI, 6.9 to 24.1], p < 0.001); and the odds of
participation were three times greater for dyads attend-
ing a private hospital for treatment than for those at-
tending a public hospital (OR = 3.08 [95% CI, 2.0 to 4.7],
p < 0.001).
Factors associated with reasons for non-participation
Reason ‘lack of time’
Bivariate analysis showed that dyads were more likely to
decline participation due to ‘lack of time’ if the patient
was younger (18–39 years, p = 0.009; 40–59 years, p =
0.001), received chemotherapy alone (p < 0.001), and
was treated at a private hospital (p = 0.019) but less
likely to decline if the patient was male (p = 0.039) and
diagnosed with lung, head and neck, melanoma, or brain
cancer (p = 0.03). In multivariable analysis, patient’s age
and treatment modality remained significantly associated
with declining participation (Table 2). Dyads, where the
patient was aged 40–59 years, were 1.5 times more likely
to decline participation due to a lack of time compared
to those aged 60+ years (OR = 1.56 [95% CI, 1.0 to 2.4],
p = 0.049), and patients receiving chemotherapy alone
were nearly twice as likely to decline participation due
to a lack of time compared to patients receiving radio-
therapy alone (OR = 1.89 [95% CI, 1.2 to 3.0], p = 0.009).
Reason ‘lack of interest’
Bivariate analysis showed that dyads were less likely to
decline participation due to ‘lack of interest’ if the
Heckel et al. BMC Medical Research Methodology          (2018) 18:146 Page 4 of 10
patient was younger (40–59 years, p = 0.039), had a
diagnosis of prostate cancer (p = 0.037), received
chemotherapy alone (p = 0.031), and was treated at a
private hospital (p = 0.019). In multivariable analysis,
cancer diagnosis and treatment modality remained
significantly associated with declining participation
(Table 2). Dyads where the patient was diagnosed
with prostate cancer compared to those diagnosed
with breast cancer (OR = 0.32 [95% CI, 0.1 to 0.7],
p = 0.004), and dyads where the patient was receiving
chemotherapy alone compared to those receiving
radiotherapy alone (OR = 0.530 [95% CI, 0.3 to 0.9],
Table 1 Profile of non-participants and participants, and factors associated with participation (N = 737)
Non-Participants
n = 521 (71%)
Participants
n = 216 (29%)
P value
Caregiver
Gendera Maleb 218 (70) 92 (30) 0.012
Female 187 (60) 124 (40)
Age Mean (SD) 56.75 (12.94) –
18–39 years 23 (11)
40–59 years 97 (45)
60+ years 96 (44)
Living situation Together 181 (84) –
Not together 35 (16)
Patient/caregiver Relationship Spouse/partner 171 (79) –
Non-spouse/partner 45 (21)
Educationa Tertiary 68 (32) –
Non-tertiary 147 (68)
Household size Median 2.00 –
Min/Max (Range) 1/8 (7)
Patient
Gender Femaleb 332 (73) 122 (27) 0.057
Male 189 (67) 94 (33)
Age Mean (SD) 59.96 (12.56) 56.29 (12.25)
60+ yearsb 284 (72) 112 (28)
40–59 years 207 (70) 90 (30) 0.592
18–39 years 30 (68) 14 (32) 0.463
Socio-economic statusa Middleb 187 (68) 88 (32)
Low 148 (76) 47 (24) 0.063
High 185 (70) 79 (30) 0.602
Cancer type Breastb 240 (73) 89 (27)
Bowel 40 (69) 18 (31) 0.722
Prostate/testicular 59 (67) 29 (33) 0.276
Lung/H&N/melanoma/brain 78 (70) 33 (30) 0.659
Haematological 55 (68) 26 (32) 0.438
Others 49 (70) 21 (30) 0.431
Treatment type Radiotherapyb 312 (81) 72 (19)
Chemotherapy 189 (70) 82 (30) 0.003
Chemoradiotherapy 20 (24) 62 (76) < 0.001
Hospital type Publicb 448 (76) 144 (24) < 0.001
Private 73 (50) 72 (50)
an varies due to missing data, breference category
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Table 2 Binary logistic regression analyses for factors associated with participation and reasons for non-participation
Unadjusted 95% CI
B S.E. Wald χ2 OR Lower Upper p-value
Participating in the study
Intercept − 1.7 0.2 81.4 0.2 < 0.001
Carer gender Female 0.5 0.2 7.7 1.7 1.2 2.4 0.005
Treatment type (reference = radiotherapy) Chemotherapy 0.3 0.2 3.1 1.4 1.0 2.1 0.080
Chemoradiotherapy 2.6 0.3 64.2 12.9 6.9 24.1 < 0.001
Hospital type Private 1.1 0.2 27.6 3.1 2.0 4.7 < 0.001
Lack of time
Intercept −1.3 0.2 38.2 0.3 < 0.001
Patient age (reference = 60–90 years) 18–39 years 0.7 0.4 2.5 1.9 0.9 4.3 0.113
40–59 years 0.4 0.2 3.9 1.6 1.0 2.4 0.049
Patient gender Male −0.2 0.3 0.4 0.8 0.4 1.5 0.529
Patient diagnosis (reference = breast cancer) Othersa − 0.5 0.4 1.2 0.6 0.3 1.4 0.271
Bowel −0.3 0.4 0.7 0.7 0.3 1.6 0.395
Prostate −0.0 0.5 0.0 1.0 0.4 2.5 0.938
Lungb −0.3 0.4 0.5 0.8 0.4 1.6 0.496
Haematological 0.0 0.4 0.0 1.0 0.5 2.2 0.982
Treatment type (reference = radiotherapy) Chemotherapy 0.6 0.2 6.9 1.9 1.2 3.0 0.009
Chemoradiotherapy 0.4 0.5 0.7 1.5 0.5 4.3 0.417
Hospital type Private 0.3 0.3 1.2 1.36 0.8 2.4 0.277
Lack of interest
Intercept −0.3 0.2 2.9 0.7 0.091
Patient age (reference = 60–90 years) 18–39 years −0.3 0.4 0.5 0.7 0.3 1.8 0.483
40–59 years −0.4 0.2 3.5 0.7 0.4 1.0 0.060
Patient diagnosis (reference = breast cancer) Others 0.6 0.3 2.8 1.8 0.9 3.5 0.097
Bowel 0.1 0.4 0.0 1.1 0.5 2.3 0.855
Prostate −1.1 0.4 8.4 0.3 0.1 0.7 0.004
Lung −0.2 0.3 0.3 0.8 0.5 1.5 0.551
Haematological 0.4 0.4 1.4 1.5 0.8 3.1 0.232
Treatment type (reference = radiotherapy) Chemotherapy −0.6 0.2 6.4 0.5 0.3 0.9 0.012
Chemoradiotherapy 0.1 0.5 0.0 1.1 0.4 2.9 0.872
Hospital type Private −0.4 0.3 1.8 0.6 0.3 1.2 0.177
Not requiring support
Intercept −1.0 0.2 20.8 0.4 < 0.001
Patient age (reference = 60–90 years) 18–39 years −1.3 0.8 2.7 0.3 0.1 1.3 0.100
40–59 years −0.3 0.2 1.2 0.8 0.5 1.2 0.270
Patient diagnosis (reference = breast cancer) Others −1.2 0.6 3.7 0.3 0.1 1.0 0.053
Bowel 0.4 0.4 1.0 1.5 0.7 3.3 0.322
Prostate 0.8 0.3 6.2 2.3 1.2 4.3 0.013
Lung −0.3 0.3 0.7 0.7 0.4 1.4 0.390
Haematological 0.0 0.4 0.0 1.0 0.4 2.5 0.928
Treatment type (reference = radiotherapy) Chemotherapy −0.6 0.3 4.1 0.5 0.3 1.0 0.042
Chemoradiotherapy −1.5 1.0 2.1 0.2 0.0 1.7 0.150
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p = 0.012) were less likely to decline participation due
to lack of interest.
Reason ‘not requiring support’
Bivariate analysis showed that dyads were more likely to
decline participation due to ‘not requiring support’ if the
patient was diagnosed with prostate cancer (p < 0.001)
and less likely to decline if the patient was younger (18–
39 years, p = 0.030; 40–59 years, p = 0.018), diagnosed
with a cancer listed as ‘other’ (e.g. gynaecological can-
cers, bladder; p = 0.039), and was receiving chemother-
apy alone (p = 0.001). In multivariable analysis, patient’s
diagnosis and treatment modality remained significantly
associated with participation (Table 2). The odds of de-
clining participation because the dyad felt they needed
no support were two times greater if the patient was di-
agnosed with prostate cancer (OR = 2.28 [95% CI, 1.2 to
4.3], p = 0.013) than for those diagnosed with breast can-
cer. Dyads where the patient was receiving chemother-
apy alone were less likely to decline due to not requiring
support compared to those receiving radiotherapy alone
(OR = 0.55 [95% CI, 0.3 to 1.0], p = 0.042).
Reason ‘too burdensome’
Bivariate analysis showed that dyads were more likely to
decline because they felt participation was too burden-
some if the patient was diagnosed with lung, head and
neck, melanoma, or brain cancer (p = 0.014), had a can-
cer listed as ‘other’ (p = 0.008), or was receiving treat-
ment at a private hospital (p = 0.044). These variables
remained significantly associated with declining partici-
pation in multivariable analysis (Table 2). The odds of
declining because the dyad felt participation would be
too burdensome were three times greater for dyads
where the patient was diagnosed with a cancer listed as
‘other’ (OR = 3.29 [95% CI, 1.5 to 7.3], p = 0.003) and al-
most three times greater for those diagnosed with lung,
head and neck, melanoma, or brain cancer (OR = 2.69
[95% CI, 1.4 to 5.3], p = 0.004) as opposed to those with
breast cancer. Dyads attending a private hospital for
treatment were twice as likely to decline participation
reporting it would be too burdensome compared to
those attending a public hospital (OR = 2.32, 95% CI, 1.2
to 4.5], p = 0.012).
Discussion
This analysis reported on the factors associated with par-
ticipation in a multi-centred randomized controlled trial.
We have provided additional informative data on the
reasons for non-participation and dyadic factors associ-
ated with those reasons, to inform the successful recruit-
ment of cancer dyads into intervention studies in the
future. Overall, 216 dyads consented from a total of 737
eligible patient/caregiver pairs, reflecting an uptake rate
of 29% which was lower than some randomized con-
trolled intervention studies involving people diagnosed
with cancer and their caregivers [7, 9, 12] but higher
than others [6, 21, 22]. Of the 102 dyads who did not
meet the selection criteria, nearly 80% reported not hav-
ing a caregiver, highlighting the need to investigate the
supportive care needs of people diagnosed with cancer
who do not have caregivers- a potentially vulnerable
group.
Caregiver gender was identified as a key factor associ-
ated with participation. Female caregivers were more
likely to participate in our study which is in line with the
literature [7, 15] and may be linked to the fact that men
are less likely to seek help than females, due to fears
about help-seeking being perceived as a sign of weakness
or as a lack of emotional control [23].
Patient related factors which influenced participation
were treatment modality and hospital type. We found
that the odds of participation in the study were 13 times
greater if the patient received chemoradiotherapy as op-
posed to radiotherapy alone. Receiving both regimes can
cause a range of side effects exceeding those from radio-
therapy alone [24]. It is possible that adverse effects
from dual treatments inflicted considerable discomfort
Table 2 Binary logistic regression analyses for factors associated with participation and reasons for non-participation (Continued)
Unadjusted 95% CI
B S.E. Wald χ2 OR Lower Upper p-value
Too burdensome
Intercept −2.3 0.2 96.4 0.1 < 0.001
Patient diagnosis (reference = breast cancer) Others 1.2 0.4 8.7 3.3 1.5 7.3 0.003
Bowel 0.4 0.5 0.8 1.6 0.6 4.1 0.367
Prostate −0.1 0.5 0.0 0.9 0.4 2.4 0.905
Lung 1.0 0.3 8.1 2.7 1.4 5.3 0.004
Haematological −0.1 0.5 0.0 0.9 0.3 2.5 0.858
Hospital type Private 0.8 0.3 6.3 2.3 1.2 4.5 0.012
aincludes gynecological, bladder, kidney, soft tissue; bincludes lung, head and neck, brain, melanoma
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to patients and may have required more intense care-
giver involvement in the management of side effects,
thereby creating a greater need for caregiver support
and a greater willingness to participate in our study. This
outcome is in line with a qualitative study conducted by
Ream et al. 2013 [25] where caregivers of patients
undergoing chemotherapy reported a lack of support to
address their information and health care needs, result-
ing in isolation and feelings of insecurity in responding
to patients’ needs.
We achieved a higher participation rate at private
compared to public hospitals. There is some evidence in
the literature suggesting that caregivers of people diag-
nosed with cancer recruited at private hospitals present
with more unmet supportive care needs compared to
those from public hospitals [26]. Therefore, higher en-
rolment of dyads at private health services may reflect
their greater need for support. Public hospitals provide
high quality medical care in Australia and are more
widely accessible, free of charge and are better equipped
to deal with more complex cases. On the other hand,
private hospitals offer more choice related to patient
care (e.g. choice of doctor) and waiting times for elective
surgery can be shorter; but to access this, people must
have private health insurance.
The most common reasons stated by dyads declining
participation were lack of interest, lack of time, not re-
quiring support, and too burdensome, and these reasons
were linked to certain patient factors such as treatment
modality, age, cancer type, and hospital type. While the
majority of dyads preferred not to elaborate on the spe-
cific reasons for declining, some stated that they were
already receiving support from family members or from
a psychologist.
Dyads, where the person with cancer was receiving
chemotherapy alone, as opposed to radiotherapy alone,
were more likely to decline because they reported they
had no time available to participate in our study. How-
ever, they were less likely to decline due to lack of inter-
est or because they felt they did not need any support.
Compared to the side effects from radiation treatment,
those from chemotherapy can be more intense [27] and
may cause greater interference with the dyad’s day to
day functioning, impacting on the time dyads had avail-
able to participate in research. On the other hand, while
chemotherapy side effects mainly occur during active
treatment and gradually disappear after treatment has
ceased, secondary effects from radiotherapy may not be
present until several months after completing treatment
[28, 29]. In addition, patients receiving radiotherapy
attended the radiation department usually on a daily
basis; being followed up and supported regularly may
minimise the need for further support at this phase of
the treatment. Further research is required to better
understand why this subgroup was less likely to partici-
pate in the study.
We also found that dyads, where the patient was
younger (< 60 years), were more likely to decline, report-
ing they were too busy and did not have the time to take
part in the study. Therefore, an intervention that takes
into account the time constraints of younger dyads re-
quires investigation. Further research into the accept-
ability and efficacy of web or app-based interventions to
support people diagnosed with cancer and their care-
givers is worth pursuing, as these modes of delivery may
offer greater flexibility in terms of the times at which
they could engage, and thereby be more suitable for
younger cancer dyads.
In terms of cancer type, compared to dyads where the
patient had breast cancer, those with lung, head and
neck, brain, and melanoma were more likely to decline,
reporting participation would be too burdensome. Our
findings are in line with previous research suggesting
lower participation rates in patients with a diagnosis
other than breast cancer [14]. The existence of an exten-
sive network of breast care nurses, and the widely held
perception that women with breast cancer and their
families are better supported than those with other diag-
noses, may explain why dyads with other cancers in our
study, who may have received little support since diag-
nosis and were coping less well, perceived research par-
ticipation as too burdensome. Further, it should be
noted that these cancers are often aggressive and treat-
ments often have debilitating side effects which can
place heavy burden on caregivers, and together with the
perceived burden of participating in research, it may
have been particularly difficult for them to take part in
the study albeit they could have benefited from the inter-
vention. However, more research is needed to support
this argument. Further, dyads where the patient was di-
agnosed with prostate cancer were more likely to decline
participation, reporting they did not need any support
but were less likely to decline due to lack of interest.
The majority of prostate cancer patients in our study
were receiving radiotherapy only (94%) and as men-
tioned previously this treatment modality is usually asso-
ciated with fewer side effects during active treatment. It
is possible that these dyads were coping well and there-
fore did not feel the need for any support. In addition,
as indicated above, research suggests different help seek-
ing behaviours in men with a greater reluctance to ask
for support compared to women, which may be associ-
ated with the lower accrual rates for prostate cancer pa-
tients found in our study [30].
There are limitations to this study. Caregiver data
available for non-participating dyads were restricted to
caregiver gender, which limited a comparison of care-
givers that enrolled and declined participation. While it
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was possible to collect information on caregiver gender
through observation during the recruitment process at
each health service, caregiver demographics were collected
through the baseline survey, which was completed by en-
rolled participants only. The difficulty experienced recruit-
ing dyads into this study was in part due to the need to
obtain consent from both the person diagnosed with can-
cer and the caregiver; we observed one party agreeing to
participate while the other chose to decline. In addition,
when recording the reasons for non-participation, it was
often difficult to specify who (the person diagnosed with
cancer or the caregiver) was responsible for declining en-
rolment. This was particularly the case during the 48 h fol-
low up calls as dyads had time to discuss their potential
participation, conversations were usually brief and did not
allow for a detailed investigation in to who made the final
decision to decline. Further, we did not collect reasons or
motivations of those dyads that chose to participate in our
trial. Future research should consider obtaining this im-
portant information, to improve recruitment of
cancer-affected dyads in the future.
Conclusions
This analysis provides important information for re-
searchers undertaking randomized controlled trials in-
volving people diagnosed with cancer and their
caregivers that should be relevant to many intervention
and epidemiological studies. We provide new insights
into factors associated with enrolling cancer dyads and
identified those who are prone to decline participation.
Male caregivers were less likely to participate in our
study, and those dyads where the patient was receiving a
combination of chemotherapy and radiotherapy and be-
ing treated at a private hospital, were more likely to take
part. Common reasons for declining participation were
lack of interest, lack of time, not requiring support, and
finding participation too burdensome. Patient factors as-
sociated with these reasons were treatment modality,
cancer type, age, and hospital type. These results may
also be useful when recruiting dyads with other chronic
illnesses. A focus on gender specific approaches would
be advantageous to increase participation of male care-
givers as they are less likely to take part in research than
females. In addition, developing programs which are
more aligned to the busy time schedules of younger
dyads, may help overcome recruitment barriers and
more importantly, address unmet needs in this popula-
tion. Further consideration should be given to the appro-
priate timing when recruiting dyads, taking into account
variations related to cancer type and treatment modality;
offering participation when the need for support is high-
est (e.g. via screening for distress and triaging to support
services accordingly). It would be advantageous to ex-
plore novel approaches such as technology-based
interventions (e.g. smartphone applications) to assist care-
givers and patients throughout their cancer trajectory, as
this mode of delivery may be perceived as less burden-
some and time consuming than a telephone-based inter-
vention. When designing intervention studies for cancer
dyads it is also important to consider the various roles
caregivers play in relation to the situation of the cancer
patient. For example, caregiver tasks can vary with the
type of cancer diagnosis as well as with the changing
needs of the patient throughout the cancer trajectory. In
addition, further research into the characteristics of pri-
vate and public healthcare environments may help explain
differences in participation rates among these health
services.
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